Ms Hewitt has a BSc (Econ Hons) from the University College in London, UK, and qualified as a Chartered Accountant FCA in 1982. In her executive career she worked for Arthur Andersen & Co., Gartmore Investment Management Ltd, UK, Citicorp Venture Capital (now CVC), 3i Group and Smith & Nephew plc, UK. Ms Hewitt serves as a member of the boards of Savills plc and Melrose Industries plc, where she is chairman of both audit committees, both in the UK. Ms Hewitt also serves as an external member of the House of Lords Commission, UK, and chairs the audit committee. Ms Hewitt was first elected to the Board of Novo Nordisk A/S in 2012 and was most recently re-elected in March 2017. Her term as a board member expires in March 2018. In March 2017, the Board of Directors of Novo Nordisk A/S assessed that Ms Hewitt is regarded as an independent board member as defined in Section 3.2.1 of the Recommendations on Corporate Governance designated by Nasdaq Copenhagen. Ms Hewitt became a member of the Audit Committee at Novo Nordisk A/S in March 2012 and chairman of the Audit Committee in March 2015. In March 2017, the Board of Directors of Novo Nordisk A/S designated Ms Hewitt as financial expert as defined by the US Securities and Exchange Commission (SEC) and assessed that Ms Hewitt qualifies as independent pursuant to the US Securities Exchange Act. In addition, the Board of Directors of Novo Nordisk A/S assessed that Ms Hewitt has competences in accounting and auditing as required by the Danish Act on Approved Auditors and Audit Firms. Ms Hewitt became a member of the Nomination Committee at Novo Nordisk A/S in April 2013. In January 2017, the Board of Directors assessed that the special competencies possessed by Ms Hewitt that are important for the performance of her duties are her extensive experience within the field of medical devices, significant financial knowledge and knowledge about how large international companies operate. Ms Hewitt is a female UK national, born November 1956. Ms Hewitt has a BSc (Econ Hons) from the University College in London, UK, and qualified as a Chartered Accountant FCA in 1982. In her executive career she worked for Arthur Andersen & Co., Gartmore Investment Management Ltd, UK, Citicorp Venture Capital (now CVC), 3i Group and Smith & Nephew plc, UK. Ms Hewitt serves as a member of the boards of Savills plc and Melrose Industries plc, where she is chairman of both audit committees, both in the UK. Ms Hewitt also serves as an external member of the House of Lords Commission, UK, and chairs the audit committee. Ms Hewitt was first elected to the Board of Novo Nordisk A/S in 2012 and was most recently re-elected in March 2017. Her term as a board member expires in March 2018. In March 2017, the Board of Directors of Novo Nordisk A/S assessed that Ms Hewitt is regarded as an independent board member as defined in Section 3.2.1 of the Recommendations on Corporate Governance designated by Nasdaq Copenhagen. Ms Hewitt became a member of the Audit Committee at Novo Nordisk A/S in March 2012 and chairman of the Audit Committee in March 2015. In March 2017, the Board of Directors of Novo Nordisk A/S designated Ms Hewitt as financial expert as defined by the US Securities and Exchange Commission (SEC) and assessed that Ms Hewitt qualifies as independent pursuant to the US Securities Exchange Act. In addition, the Board of Directors of Novo Nordisk A/S assessed that Ms Hewitt has competences in accounting and auditing as required by the Danish Act on Approved Auditors and Audit Firms. Ms Hewitt became a member of the Nomination Committee at Novo Nordisk A/S in April 2013. In January 2017, the Board of Directors assessed that the special competencies possessed by Ms Hewitt that are important for the performance of her duties are her extensive experience within the field of medical devices, significant financial knowledge and knowledge about how large international companies operate. Ms Hewitt is a female UK national, born November 1956.

Pathology